Logo image of ARBS.MI

ARTERRA BIOSCIENCE SPA (ARBS.MI) Stock Earnings & Estimates

Europe - Euronext Milan - BIT:ARBS - IT0005386369 - Common Stock

3.08 EUR
+0.06 (+1.99%)
Last: 12/22/2025, 7:00:00 PM

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2022 2023 2024
Revenue
YoY % growth
ARBS.MI revenue by date.ARBS.MI revenue by date.
3.564M
-6.84%
3.304M
-7.28%
4.173M
26.30%
EBITDA
YoY % growth
ARBS.MI ebitda by date.ARBS.MI ebitda by date.
2.133M
22.88%
1.592M
-25.37%
1.712M
7.60%
EBIT
YoY % growth
ARBS.MI ebit by date.ARBS.MI ebit by date.
1.601M
28.24%
1.059M
-33.83%
1.373M
29.64%
Operating Margin
ARBS.MI operating margin by date.ARBS.MI operating margin by date.
44.92%32.06%32.91%
EPS
YoY % growth
ARBS.MI eps by date.ARBS.MI eps by date.
N/AN/AN/A

All data in EUR

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in EUR

Recent Earnings VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Recent Revenue VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q2 2025
Q2Q % growth
2.572M
14.28%
%
Q4 2024
Q2Q % growth
1.922M
12.32%
%
Q2 2024
Q2Q % growth
2.251M
41.30%
%
Q2 2023
Q2Q % growth
1.593M
-25.09%
%
Q2 2022
Q2Q % growth
2.126M
25.46%
%
Q4 2021
Q2Q % growth
2.131M
62.06%
%
Q2 2021
Q2Q % growth
1.695M
12.47%
%
Q4 2020
Q2Q % growth
1.315M
12.31%
%
Q2 2020
Q2Q % growth
1.507M
-2.06%
%
ARBS.MI Yearly Revenue VS EstimatesARBS.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A